Douglas D. Thomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Douglas D. Thomas has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
Jason R. Hickok
IRBM S.p.A ., IRBM Science Park, Via Pontina Km. 30.600 , I-00071 Pomezia (Rome) , Italy
10 shared publicationsDivya Vasudevan
University of Illinois Chicago, College of Pharmacy, Department of Pharmaceutical Sciences, Chicago, IL, USA
7 shared publications- David A. Wink
Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, USA
5 shared publications - Daniel W. McVicar
Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, Frederick MD 21702, USA
4 shared publications - Sharon A. Glynn
Discipline of Pathology, Lambe Institute for Translational Research, School of Medicine, University of Galway, Galway, Ireland
4 shared publications Hannah Petraitis Kuschman
Department of Pharmaceutical Sciences, University of Illinois Chicago, College of Pharmacy, Chicago, USA
3 shared publications
Latest Publications
- Open Access
- 16 August 2026
- Published by Elsevier in Redox Biology
- Vol. 96
Chronic nitric oxide mediates dual-layer gene regulation through mRNA m6A positional remodeling and parallel transcriptional reprogramming
- 16 August 2026
- Published by Elsevier in Redox Biology
- Vol. 96
Open AccessChronic nitric oxide mediates dual-layer gene regulation through mRNA m6A positional remodeling and parallel transcriptional reprogramming
- Open Access
- 2 June 2026
- Published by Elsevier in Redox Biology
- Vol. 95, 104245
Nitric oxide-driven Warburg reprogramming at the NOS2-COX2 axis: An integrative engine of cancer hallmarks
- 2 June 2026
- Published by Elsevier in Redox Biology
- Vol. 95, 104245
Open AccessNitric oxide-driven Warburg reprogramming at the NOS2-COX2 axis: An integrative engine of cancer hallmarks
- Open Access
- 15 April 2026
- Published by Elsevier in Redox Biology
- Vol. 93, 104170
Nitric oxide generates a coordinated histone modification signature consistent with chromatin compaction, linked to methyl-modifying enzyme dysregulation and tumor-permissive gene silencing
- 15 April 2026
- Published by Elsevier in Redox Biology
- Vol. 93, 104170
Open AccessNitric oxide generates a coordinated histone modification signature consistent with chromatin compaction, linked to methyl-modifying enzyme dysregulation and tumor-permissive gene silencing
- Open Access
- 4 June 2025
- Published by Elsevier in Redox Biology
- Vol. 85, 103699
Nitric Oxide restricts iron availability and induces quorum sensing in Streptococcus pyogenes
- 4 June 2025
- Published by Elsevier in Redox Biology
- Vol. 85, 103699
Open AccessNitric Oxide restricts iron availability and induces quorum sensing in Streptococcus pyogenes
- Open Access
- 18 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Nitric oxide inhibits ten-eleven translocation DNA demethylases to regulate 5mC and 5hmC across the genome
DNA methylation at cytosine bases (5-methylcytosine, 5mC) is a heritable epigenetic mark regulating gene expression. While enzymes that metabolize 5mC are well-characterized, endogenous signaling molecules that regulate DNA methylation machinery have not been described. We report that physiological nitric oxide (NO) concentrations reversibly inhibit the DNA demethylases TET and ALKBH2 by binding to the mononuclear non-heme iron atom forming a dinitrosyliron complex (DNIC) and preventing cosubstrates from binding. In cancer cells treated with exogenous NO, or endogenously synthesizing NO, 5mC and 5-hydroxymethylcytosine (5hmC) increase, with no changes in DNA methyltransferase activity. 5mC is also significantly increased in NO-producing patient-derived xenograft tumors from mice. Genome-wide methylome analysis of cells chronically treated with NO (10 days) shows enrichment of 5mC and 5hmC at gene-regulatory loci, correlating with altered expression of NO-regulated tumor-associated genes. Regulation of DNA methylation is distinctly different from canonical NO signaling and represents a unique epigenetic role for NO.
- 18 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Open AccessNitric oxide inhibits ten-eleven translocation DNA demethylases to regulate 5mC and 5hmC across the genome
DNA methylation at cytosine bases (5-methylcytosine, 5mC) is a heritable epigenetic mark regulating gene expression. While enzymes that metabolize 5mC are well-characterized, endogenous signaling molecules that regulate DNA methylation machinery have not been described. We report that physiological nitric oxide (NO) concentrations reversibly inhibit the DNA demethylases TET and ALKBH2 by binding to the mononuclear non-heme iron atom forming a dinitrosyliron complex (DNIC) and preventing cosubstrates from binding. In cancer cells treated with exogenous NO, or endogenously synthesizing NO, 5mC and 5-hydroxymethylcytosine (5hmC) increase, with no changes in DNA methyltransferase activity. 5mC is also significantly increased in NO-producing patient-derived xenograft tumors from mice. Genome-wide methylome analysis of cells chronically treated with NO (10 days) shows enrichment of 5mC and 5hmC at gene-regulatory loci, correlating with altered expression of NO-regulated tumor-associated genes. Regulation of DNA methylation is distinctly different from canonical NO signaling and represents a unique epigenetic role for NO.
- Open Access
- 3 April 2024
- Published by Springer Nature in Research Square
Nitric oxide inhibits ten-eleven translocation DNA demethylases to regulate 5mC and 5hmC across the genome
DNA methylation at cytosine bases of eukaryotic DNA (5-methylcytosine, 5mC) is a heritable epigenetic mark that can regulate gene expression in health and disease. Enzymes that metabolize 5mC have been well-characterized, yet the discovery of endogenously produced signaling molecules that regulate DNA methyl-modifying machinery have not been described. Herein, we report that the free radical signaling molecule nitric oxide (NO) can directly inhibit the Fe(II)/2-OG-dependent DNA demethylases ten-eleven translocation (TET) and human AlkB homolog 2 (ALKBH2). Physiologic NO concentrations reversibly inhibited TET and ALKBH2 demethylase activity by binding to the mononuclear non-heme iron atom which formed a dinitrosyliron complex (DNIC) preventing cosubstrates (2-OG and O2) from binding. In cancer cells treated with exogenous NO, or cells endogenously synthesizing NO, there was a global increase in 5mC and 5-hydroxymethylcytosine (5hmC) in DNA, the substrates for TET, that could not be attributed to increased DNA methyltransferase activity. 5mC was also elevated in NO-producing cell-line-derived mouse xenograft and patient-derived xenograft tumors. Genome-wide DNA methylome analysis of cells chronically treated with NO (10 days) demonstrated enrichment of 5mC and 5hmC at gene-regulatory loci which correlated to changes in the expression of NO-regulated tumor-associated genes. Regulation of DNA methylation is distinctly different from canonical NO signaling and represents a novel epigenetic role for NO.
- 3 April 2024
- Published by Springer Nature in Research Square
Open AccessNitric oxide inhibits ten-eleven translocation DNA demethylases to regulate 5mC and 5hmC across the genome
DNA methylation at cytosine bases of eukaryotic DNA (5-methylcytosine, 5mC) is a heritable epigenetic mark that can regulate gene expression in health and disease. Enzymes that metabolize 5mC have been well-characterized, yet the discovery of endogenously produced signaling molecules that regulate DNA methyl-modifying machinery have not been described. Herein, we report that the free radical signaling molecule nitric oxide (NO) can directly inhibit the Fe(II)/2-OG-dependent DNA demethylases ten-eleven translocation (TET) and human AlkB homolog 2 (ALKBH2). Physiologic NO concentrations reversibly inhibited TET and ALKBH2 demethylase activity by binding to the mononuclear non-heme iron atom which formed a dinitrosyliron complex (DNIC) preventing cosubstrates (2-OG and O2) from binding. In cancer cells treated with exogenous NO, or cells endogenously synthesizing NO, there was a global increase in 5mC and 5-hydroxymethylcytosine (5hmC) in DNA, the substrates for TET, that could not be attributed to increased DNA methyltransferase activity. 5mC was also elevated in NO-producing cell-line-derived mouse xenograft and patient-derived xenograft tumors. Genome-wide DNA methylome analysis of cells chronically treated with NO (10 days) demonstrated enrichment of 5mC and 5hmC at gene-regulatory loci which correlated to changes in the expression of NO-regulated tumor-associated genes. Regulation of DNA methylation is distinctly different from canonical NO signaling and represents a novel epigenetic role for NO.
- Open Access
- 14 October 2023
- Published by Elsevier in Redox Biology
- Vol. 67, 102928
Nitric oxide inhibits FTO demethylase activity to regulate N6-methyladenosine mRNA methylation
- 14 October 2023
- Published by Elsevier in Redox Biology
- Vol. 67, 102928
Open AccessNitric oxide inhibits FTO demethylase activity to regulate N6-methyladenosine mRNA methylation
- Open Access
- 14 March 2023
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 404 (7)
Frontmatter
Article Frontmatter was published on June 1, 2023 in the journal Biological Chemistry (volume 404, issue 7).
- 14 March 2023
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 404 (7)
Open AccessFrontmatter
Article Frontmatter was published on June 1, 2023 in the journal Biological Chemistry (volume 404, issue 7).
- 1 January 2023
- Published by Begell House Inc. Publishers in Critical Reviews™ in Oncogenesis
- Vol. 28 (1) , 27-45
The Chemical Biology of NO that Regulates Oncogenic Signaling and Metabolism: NOS2 and Its Role in Inflammatory Disease
Nitric oxide (NO) and the enzyme that synthesizes it, nitric oxide synthase 2 (NOS2), have emerged as key players in inflammation and cancer. Expression of NOS2 in tumors has been correlated both with positive outcomes and with poor prognoses. The chemistry of NO is the major determinate to the biological outcome and the concentration of NO, which can range over five orders of magnitude, is critical in determining which pathways are activated. It is the activation of specific oncogenic and immunological mechanisms that shape the outcome. The kinetics of specific reactions determine the mechanisms of action. In this review, the relevant reactions of NO and related species are discussed with respect to these oncogenic and immunological signals.
- 1 January 2023
- Published by Begell House Inc. Publishers in Critical Reviews™ in Oncogenesis
- Vol. 28 (1) , 27-45
The Chemical Biology of NO that Regulates Oncogenic Signaling and Metabolism: NOS2 and Its Role in Inflammatory Disease
Nitric oxide (NO) and the enzyme that synthesizes it, nitric oxide synthase 2 (NOS2), have emerged as key players in inflammation and cancer. Expression of NOS2 in tumors has been correlated both with positive outcomes and with poor prognoses. The chemistry of NO is the major determinate to the biological outcome and the concentration of NO, which can range over five orders of magnitude, is critical in determining which pathways are activated. It is the activation of specific oncogenic and immunological mechanisms that shape the outcome. The kinetics of specific reactions determine the mechanisms of action. In this review, the relevant reactions of NO and related species are discussed with respect to these oncogenic and immunological signals.
- 9 March 2022
- Published by Elsevier in Nitric Oxide
- Vol. 122-123, 45-46
Methods to the madness – Fundamental techniques in NO research
- 9 March 2022
- Published by Elsevier in Nitric Oxide
- Vol. 122-123, 45-46
Methods to the madness – Fundamental techniques in NO research